Xeris Biopharma Holdings (XERS) EBT Margin Growth (3y) (2023 - 2026)

Xeris Biopharma Holdings (XERS) EBT Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 1,840.00
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -134.00
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -5,626.00
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1,686.00
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -1,570.00
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 5,487.00
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -225.00
10 Xeris Biopharma Holdings 1.43 Bn 1.32 Bn 72.55 Mn 5,340.00

Historic Data

Download Data
DateValue
Mar 31, 2026 5,340.00
Dec 31, 2025 5,295.00
Sep 30, 2025 7,542.00
Jun 30, 2025 10,212.00
Mar 31, 2025 13,925.00
Dec 31, 2024 22,851.00
Sep 30, 2024 20,004.00
Jun 30, 2024 27,929.00
Mar 31, 2024 17,871.00
Dec 31, 2023 27,911.00
Sep 30, 2023 14,429.00